جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

124 مُخرَج نتائج البحث عن «Meta-analysis»

مراجعةمفتوح (مستودع)20266استشهاد· Semantic Scholar

Perioperative outcomes and safety of Uniportal Robotic-Assisted Thoracic Surgery (U-RATS) for anatomic lung resection: a systematic review and meta-analysis

Journal of Robotic Surgery · مجلد 20 (1)

Uniportal robotic-assisted thoracic surgery (U-RATS) represents a recent evolution in minimally invasive lung resection, combining the single-incision philosophy with robotic technology. However, its perioperative safety and outcomes have not been clearly defined across published studies. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and a registered protocol. PubMed, Web of Science, and the Cochrane Library were searched for studies reporting perioperative outcomes of U-RATS for anatomic lung resection in adults. Primary outcomes included conversion rate, morbidity, and mortality. Secondary outcomes were operative time, estimated blood loss, length of hospital stay, and lymph node yield. Random-effects models were applied to pool estimates. Sixteen studies encompassing 579 patients were included. The pooled conversion rate was 1.34% (95% CI: 0.42–4.15%), with no observed heterogeneity. The pooled postoperative morbidity rate was 5.99% (95% CI: 4.46–7.91%), and the pooled mortality rate was 0.21% (95% CI: 0.07–0.64%). The pooled mean operative time was 171.3 min, the estimated blood loss was 51.9 mL, and the postoperative length of stay was 4.9 days. Across 11 studies, the pooled lymph node yield was 16.6 nodes (95% CI: 14.0–19.2; I² = 89.8%). Current evidence suggests that U-RATS is a safe and feasible approach for anatomic lung resection, with low conversion and complication rates and acceptable perioperative outcomes comparable to established minimally invasive techniques.

anatomical lung resectionperioperative outcomesconversion ratepostoperative morbidity
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (3) · e106154-e106154

Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.

melasmalaser therapyQ-switched Nd:YAG laserpicosecond laser
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (2) · e103029-e103029

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.

ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Safety and efficacy of remimazolam in general anaesthesia during laparoscopic cholecystectomy: A systematic review and meta-analysis of randomised controlled trials

Indian Journal of Anaesthesia · مجلد 70 (1) · 79-91

Background and Aims: Laparoscopic cholecystectomy (LC) presents anaesthetic challenges such as haemodynamic instability and postoperative complications. Remimazolam (RMZ), a novel ultra-short acting benzodiazepine, has emerged as a promising alternative to the standard propofol, with a potentially superior safety profile. This study aimed to compare the efficacy and safety of RMZ with propofol for anaesthesia during LC. Methods: A systematic review and meta-analysis were conducted to synthesise evidence from randomised controlled trials (RCTs). A search of PubMed, Web of Science, Scopus, and Google Scholar through May 2025 was conducted. We pooled dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and 95% confidence intervals (CIs). Results: Six RCTs involving 452 patients were included in the analysis. Compared to the control group, RMZ was associated with a significantly longer anaesthesia onset time (MD: 13.26, 95% CI: 0.47, 26.05, P = 0.04), recovery time (MD: 2.72, 95% CI: 0.44, 5.01, P = 0.02), and postanaesthesia care unit (PACU) stay (MD: 5.54, 95% CI: 0.86, 10.22, P = 0.02). However, RMZ significantly reduced the incidence of injection pain (RR: 0.03, 95% CI: 0.01, 0.15, P < 0.001), and no significant differences were observed in surgery duration ( P = 0.30), extubation time ( P = 0.14), or the incidence of hypotension ( P = 0.15), bradycardia ( P = 0.13), or postoperative nausea and vomiting ( P = 0.67). Conclusion: With uncertain evidence, RMZ significantly prolonged anaesthesia onset time, recovery time, and time to PACU discharge compared to control in patients undergoing LC. Still, RMZ improved patient comfort through significantly decreased incidence of injection pain and is associated with a comparable haemodynamic safety profile to propofol.

remimazolampropofollaparoscopic cholecystectomygeneral anesthesia
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Single level versus multi-level lumbar interbody fusion for lumbar degenerative diseases: a systematic review and meta analysis

Journal of Orthopaedic Surgery and Research · مجلد 21 (1)

BACKGROUND: Degenerative spondylolisthesis affects approximately 39 million patients worldwide. While consensus supports decompression with fusion for single-level pathology, optimal surgical approaches for multi-level disease remain disputed. Despite the frequency of this clinical presentation, evidence comparing outcomes between Single-Level versus Multi-Level interbody fusion procedures is surprisingly scarce. This study aims to determine how the level of interbody fusion extent impacts outcomes in patients undergoing lumbar fusion for degenerative spondylolisthesis. METHODS: Our systematic review methodology involved comprehensive database searches (Web of Science, Scopus, PubMed, and Cochrane Library) from inception through April 2025. Two independent reviewers performed article screening, data extraction, and quality assessment. Statistical analyses used R software (v4.4.2), with outcomes reported as risk ratios for categorical variables and mean differences for continuous measures (95% CI). The certainty of evidence was assessed using the GRADE approach. RESULTS: Our meta-analysis evaluated 10 studies (N = 1430 patients; 971 Single-Level, 366 Double-Level, 198 Multi-Level fusions). Single-Level procedures demonstrated 41% lower revision rates (RR = 0.59 [0.40-0.86], p = 0.007). Operative advantages included reduced surgical time (-60.73 min [- 80.89 to - 40.57], p < 0.001), blood loss (-286.99mL [- 496.71 to - 77.27], p = 0.007), and hospitalization (-1.22 days [- 2.09 to - 0.34], p = 0.006). Oswestry Disability Index (ODI) scores showed borderline improvement (-3.90 [- 7.89 to 0.10], p = 0.06). Screw loosening decreased by 84% (RR = 0.16 [0.08-0.34], p < 0.001). We observed no significant differences in lumbar lordosis (-0.01 [- 1.75 to 1.72], p = 0.99), infection rates (RR = 0.49 [0.19-1.25], p = 0.13), adjacent segment deterioration, vascular injuries, or dural tears. The certainty of evidence ranged from low to very low, and high heterogeneity was observed in perioperative outcomes. CONCLUSIONS: Single-level fusion may offer a more favorable perioperative profile than double- or multi-level constructs, including lower revision risk, shorter operative time, reduced blood loss, shorter hospitalization, and fewer screw loosening events in pooled analyses. However, complications did not differ significantly between groups. Given substantial heterogeneity for perioperative outcomes and generally low to very low certainty of evidence, these findings should be interpreted cautiously and individualized to patient pathology and surgical context.

lumbar interbody fusiondegenerative spondylolisthesismultilevel fusionsingle-level fusion
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Association Between Maternal C-Reactive Protein (CRP) Levels and Adverse Neonatal Outcomes: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (6) · 2114-2114

Background: C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in adverse pregnancy and neonatal outcomes. However, the relationship between maternal CRP and neonatal complications remains unclear. We conducted a systematic review and meta-analysis to synthesize available evidence. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library up to July 2025 for observational studies reporting maternal CRP levels in relation to neonatal outcomes. Eligible outcomes included preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and stillbirth. Random-effects models were used to calculate pooled standardized mean differences (SMD) or odds ratios (OR) with 95% confidence intervals (CI). Statistical heterogeneity was assessed using the I2 statistic. Results: The search yielded 6843 records, of which 42 studies (comprising 18,393 pregnant women) met the inclusion criteria. Maternal mean CRP levels were significantly higher in adverse pregnancy outcomes compared with controls (SMD = 0.39; 95% CI 0.08–0.70; p = 0.01; I2 = 96.6%). Elevated CRP was strongly associated with PTB (OR = 3.81; 95% CI 2.66–5.47; p < 0.001; I2 = 85%; n = 23) and LBW (OR = 2.34; 95% CI 1.35–4.03; p = 0.002; I2 = 84.2%; n = 7). No significant associations were observed for SGA (OR = 1.14; 95% CI 0.86–1.49; p = 0.36; I2 = 0%; n = 5) or stillbirth (OR = 1.89; 95% CI 0.92–3.90; p = 0.08; I2 = 44.9%; n = 4). Conclusion: Maternal CRP is significantly associated with increased risks of preterm birth and low birth weight but not with SGA or stillbirth. These findings support the role of systemic inflammation in adverse neonatal outcomes and highlight the need for prospective studies to clarify causal mechanisms and assess the clinical utility of CRP in pregnancy risk stratification.

C-reactive proteinmaternal inflammationpreterm birthlow birth weight
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Efficacy of Selective Serotonin Reuptake Inhibitors for the Treatment of Chronic Pain and Comorbid Depression in Individuals With Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (2) · e102998-e102998

Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.

fibromyalgiaselective serotonin reuptake inhibitorscomorbid depressionchronic widespread pain
مراجعةوصول مفتوح2026

Early prophylactic low-dose hydrocortisone for bronchopulmonary dysplasia prevention in extremely preterm infants: a systematic review and meta-analysis

Frontiers in Pediatrics · مجلد 14

Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.

cortisolbronchopulmonary dysplasiaextremely preterm infantsadrenal insufficiency
مراجعةوصول مفتوح2026

Comparative Clinical Outcomes of Fractional CO₂ Laser-Assisted Topical Therapy for Nail Psoriasis: A Systematic Review

Cureus

Fractional carbon dioxide (FCO₂) laser-assisted topical therapy has been investigated to enhance drug delivery in nail psoriasis, but improvement from baseline does not establish whether laser pretreatment provides additional clinical benefit.This systematic review evaluated the comparative efficacy, safety, tolerability, and durability of FCO₂-assisted topical therapy.PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through September 18, 2026.Comparative controlled studies were eligible, and risk of bias was assessed using the Cochrane RoB 2 tool.Five studies involving 134 participants were included.Three compared FCO₂-assisted topical therapy with the same topical agent alone, one compared two FCO₂-assisted topical regimens, and one compared laser-assisted topical corticosteroid therapy with intralesional corticosteroid treatment.Although nail severity improved over time across studies, direct comparative effects were inconsistent and varied by topical agent, comparator, and assessment time.Between-treatment advantages were observed in selected tazarotene and methotrexate comparisons, whereas other comparisons showed no clear incremental benefit.Laser-assisted corticosteroid treatment achieved broadly comparable short-term outcomes to intralesional therapy with less procedural pain and greater patient satisfaction.Four of five principal efficacy results were at high risk of bias, and one raised some concerns.Meta-analysis was not appropriate because of substantial heterogeneity.Current evidence does not establish a consistent incremental efficacy advantage of laser assistance.More rigorous, adequately powered trials with appropriate paired analyses and standardized follow-up are needed before routine adjunctive use can be recommended.

nail psoriasisfractional CO2 lasertopical treatmentclinical outcomes
مقالوصول مفتوح2026

Sleep-Disordered Breathing in Children with Down Syndrome in Saudi Arabia: Current Evidence and a Proposed Care Pathway

Children · مجلد 13 (11) · 1464-1464

Background/Objectives: Children with Down syndrome are at increased risk of obstructive sleep apnea (OSA), which cannot be reliably excluded by symptoms or examination. Saudi evidence remains limited. This review synthesizes international and Saudi evidence and proposes a pediatric care pathway incorporating the transition to adult services. Methods: We conducted a structured narrative review of the English-language literature identified through PubMed/MEDLINE, selected journal websites, and reference lists. The review focused on publications from January 2018 to 17 September 2026, retaining relevant earlier studies. Evidence was synthesized qualitatively without a new meta-analysis or formal risk of bias assessment. Results: Published international estimates indicate that OSA affects approximately 50–79% of children with Down syndrome. American Academy of Pediatrics guidance recommends polysomnography (PSG) at ages 3–4 years regardless of symptoms, with earlier assessment when indicated. Nonrandomized infant intervention studies suggest potential benefits but do not establish an optimal universal screening schedule. Saudi evidence includes a small earlier PSG referral cohort and more recent caregiver surveys; no nationally representative PSG-confirmed prevalence study was identified. Arabic questionnaire validation in a mixed pediatric referral cohort does not establish Down syndrome-specific diagnostic accuracy. Published treatment evidence indicates that adenotonsillectomy often improves OSA, although residual disease commonly requires objective reassessment and individualized management. Conclusions: The evidence supports age-based PSG, earlier assessment when indicated, postoperative reassessment, and individualized multidisciplinary care. Building on this evidence, we propose a Saudi pathway linking referral tracking, family-centered positive airway pressure support, and coordinated transition. Regional networks and registry development remain unevaluated implementation proposals requiring stakeholder consultation, resource assessment, and pilot testing; they do not constitute an endorsed national guideline.

Down syndromeobstructive sleep apneasleep-disordered breathingpolysomnography screening
مقالوصول مغلق2026

Diagnostic Accuracy of Artificial Intelligence versus Clinical Diagnosis in Detecting Acute Otitis Media: A Systematic Review and Meta-analysis

Saudi Journal of Otorhinolaryngology Head and Neck Surgery

Abstract Acute otitis media (AOM) represents a prevalent infection in children globally, leading to considerable morbidity and imposing a substantial burden on healthcare systems. Prompt and precise diagnosis is critical to reducing complications, such as tympanic membrane perforation, hearing impairment, and excessive antibiotic prescribing. Advances in artificial intelligence (AI), particularly deep learning, have created opportunities to enhance diagnostic accuracy and broaden access to care, especially in low-resource settings. This systematic review and meta-analysis aimed to evaluate the diagnostic performance of AI-based systems for detecting AOM compared with conventional clinical diagnosis and to analyze their accuracy relative to human clinicians across different model architectures and diagnostic methods. Following PRISMA-DTA standards and PROSPERO registration, systematic searches were conducted in PubMed, Web of Science, and IEEE Xplore up to July 30, 2025. Eligible studies included human participants with suspected AOM, employed AI-driven diagnostic approaches, and used a clinical reference standard. The Quality Assessment of Diagnostic Accuracy Studies-2 tool assessed bias, and pooled sensitivity and specificity were estimated using a bivariate random-effects model. Nine studies published between 2020 and 2025 met the inclusion criteria. The pooled sensitivity and specificity were 91% (95% confidence interval [CI]: 77%–97%) and 99% (95% CI: 94%–100%), respectively. AI models overall matched or outperformed general practitioners and pediatricians, approaching otolaryngologist-level accuracy. AI-based tools have the potential to improve AOM detection, mitigate inequalities in healthcare access, and promote more effective diagnosis, particularly in underserved regions.

acute otitis mediaartificial intelligencedeep learningdiagnostic accuracy
مراجعةوصول مفتوح2026

Evaluating the therapeutic benefit of bacterial lysates in chronic obstructive pulmonary disease: a systematic review and meta-analysis

Frontiers in Medicine · مجلد 13

Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.

chronic obstructive pulmonary diseasebacterial extractsCOPD exacerbationshospitalization
مراجعةمفتوح (مستودع)2026

Comparative Efficacy and Safety of Intranasal Opioids versus Intravenous Morphine for Acute Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Emergency Medicine

Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.

intravenous morphineanalgesic efficacyadverse eventsrescue analgesia